Search

(C) NAbs titers among the booster dose vaccine recipients against B.1, Delta, Beta and Omicron variants. Keywords: Covaxin; booster dose; neutralizing antibody; variants of concern EN Covaxin booster dose neutralizing antibody variants of concern 1 3 3 06/08/22 20220401 NES 220401 In randomized, double-blind, multicentre phase 2 trial, the humoral and a cell-mediated responses and safety of a whole-virion inactivated SARS-CoV-2 vaccine (BBV152) in volunteers as per the Clinical Trials number: NCT04471519 showed that two doses of BBV152 (Covaxin) elicited robust neutralizing antibody responses with T cell and B cells. [Extracted from the article]

The GMT ratio of B.1 to Delta was 4.2, indicating a significant reduction in neutralization titers for Delta as compared with B.1 (Figure 1B). Keywords: first wave; second wave; neutralizing antibody; SARS CoV-2; variants of concerns; Delta variant; India EN first wave second wave neutralizing antibody SARS CoV-2 variants of concerns Delta variant India 1 3 3 06/08/22 20220401 NES 220401 The emergence of multiple variants of concerns like Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2) and other variants, such as Epsilon (B.1.427/B.1.1429), Zeta (P.2), Eta (B.1.525), Theta (P3), Iota (B.1.526) and Kappa (B.1.617.1) has contributed to the worldwide development of multiple waves of the formidable COVID-19 pandemic.[1] Mid-September 2020 was associated with a maximal spike in the daily cases in India, with its lowest case load in January 2021 during the first wave with the G Clade (with D614G mutation-B.1) being causal. [Extracted from the article]